Lamotrigine controlled-release

Drug Profile

Lamotrigine controlled-release

Alternative Names: Lamictal XR; Lamotrigine CR; Lamotrigine ER; Lamotrigine extended-release

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiepileptic drugs; Small molecules; Triazines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy

Most Recent Events

  • 14 Jun 2016 Biomarkers information updated
  • 08 Jan 2013 Generic equivalent available in USA
  • 25 Apr 2011 Launched for Partial seizures (conversion to monotherapy in patients taking one anti-epileptic drug) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top